Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors
Kate F Whitecross, Amber E Alsop, Leonie A Cluse, Adrian Wiegmans, Kellie-Marie Banks, Claudia Coomans, Melissa J Peart, Andrea Newbold, Ralph K Lindemann, Ricky W Johnstone
Blood | AMER SOC HEMATOLOGY | Published : 2009
Awarded by NHMRC (Canberra, Australia)
We thank David Huang, Andreas Strasser, Clare Scott, Jerry Adams, Suzanne Cory, and Alan Harris from the Walter and Eliza Hall Institute for helpful advice, Eu-myc mice, and cDNAs for Bcl-2, Bcl-X<INF>L</INF>, Bcl-w, Mcl-1, and A1. We thank Drs Saul Rosenberg, Steve Elmore, Alex Shoemaker, and Victoria Richon for helpful advice and providing reagents. Vorinostat was kindly provided by Merck, and ABT-737 was kindly provided by Abbott Laboratories.R.W.J. is a Pfizer Australia Research Fellow and is supported by a NHMRC (Canberra, Australia) Program Grant 251608, the Cancer Council Victoria (Melbourne, Australia), the Leukemia Foundation of Australia (Box Hill, Australia), and the Bennelong Foundation (Melbourne, Australia).